Micro-Tech (Nanjing) Co.,Ltd

SHSE:688029 Stock Report

Market Cap: CN¥13.7b

Micro-Tech (Nanjing)Ltd Valuation

Is 688029 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 688029 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 688029 (CN¥74.3) is trading above our estimate of fair value (CN¥48.2)

Significantly Below Fair Value: 688029 is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 688029?

Key metric: As 688029 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 688029. This is calculated by dividing 688029's market cap by their current earnings.
What is 688029's PE Ratio?
PE Ratio25.3x
EarningsCN¥550.49m
Market CapCN¥13.68b

Price to Earnings Ratio vs Peers

How does 688029's PE Ratio compare to its peers?

The above table shows the PE ratio for 688029 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average21.6x
301371 Harbin Fuerjia Technology
19.9x8.4%CN¥14.5b
600529 Shandong Pharmaceutical GlassLtd
19.1x18.4%CN¥16.8b
300595 Autek China
27.2x16.8%CN¥17.5b
688016 Shanghai MicroPort Endovascular MedTech
20.3x20.3%CN¥12.8b
688029 Micro-Tech (Nanjing)Ltd
25.3x19.0%CN¥13.7b

Price-To-Earnings vs Peers: 688029 is expensive based on its Price-To-Earnings Ratio (25.3x) compared to the peer average (21.6x).


Price to Earnings Ratio vs Industry

How does 688029's PE Ratio compare vs other companies in the CN Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
688029 25.3xIndustry Avg. 36.1xNo. of Companies14PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 688029 is good value based on its Price-To-Earnings Ratio (25.3x) compared to the CN Medical Equipment industry average (36.1x).


Price to Earnings Ratio vs Fair Ratio

What is 688029's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

688029 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio25.3x
Fair PE Ratio26.3x

Price-To-Earnings vs Fair Ratio: 688029 is good value based on its Price-To-Earnings Ratio (25.3x) compared to the estimated Fair Price-To-Earnings Ratio (26.3x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 688029 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥74.30
CN¥90.53
+21.8%
5.0%CN¥95.05CN¥86.00n/a2
Nov ’25CN¥71.26
CN¥90.53
+27.0%
5.0%CN¥95.05CN¥86.00n/a2
Oct ’25CN¥76.60
CN¥81.29
+6.1%
1.6%CN¥82.58CN¥80.00n/a2
Sep ’25CN¥60.79
CN¥81.29
+33.7%
1.6%CN¥82.58CN¥80.00n/a2
Aug ’25CN¥59.88
CN¥100.76
+68.3%
5.4%CN¥106.16CN¥95.36n/a2
Jul ’25CN¥61.60
CN¥100.76
+63.6%
5.4%CN¥106.16CN¥95.36n/a2
Jun ’25CN¥65.10
CN¥100.76
+54.8%
5.4%CN¥106.16CN¥95.36n/a2
May ’25CN¥72.66
CN¥100.76
+38.7%
5.4%CN¥106.16CN¥95.36n/a2
Apr ’25CN¥69.70
CN¥103.76
+48.9%
2.3%CN¥106.16CN¥101.35n/a2
Mar ’25CN¥73.28
CN¥97.54
+33.1%
9.2%CN¥106.16CN¥85.11n/a3
Feb ’25CN¥68.60
CN¥97.54
+42.2%
9.2%CN¥106.16CN¥85.11n/a3
Jan ’25CN¥96.80
CN¥97.49
+0.7%
9.2%CN¥106.16CN¥85.11n/a3
Dec ’24CN¥94.56
CN¥97.49
+3.1%
9.2%CN¥106.16CN¥85.11n/a3
Nov ’24CN¥87.68
CN¥97.49
+11.2%
9.2%CN¥106.16CN¥85.11CN¥71.263
Oct ’24CN¥76.49
CN¥97.74
+27.8%
9.3%CN¥106.16CN¥85.11CN¥76.603
Sep ’24CN¥77.21
CN¥97.74
+26.6%
9.3%CN¥106.16CN¥85.11CN¥60.793
Aug ’24CN¥78.45
CN¥104.77
+33.5%
1.3%CN¥106.16CN¥103.37CN¥59.882
Jul ’24CN¥81.56
CN¥104.77
+28.5%
1.3%CN¥106.16CN¥103.37CN¥61.602
Jun ’24CN¥88.88
CN¥104.77
+17.9%
1.3%CN¥106.16CN¥103.37CN¥65.102
May ’24CN¥89.38
CN¥104.77
+17.2%
1.3%CN¥106.16CN¥103.37CN¥72.662
Apr ’24CN¥74.51
CN¥113.93
+52.9%
6.8%CN¥121.70CN¥106.16CN¥69.702
Mar ’24CN¥82.75
CN¥113.93
+37.7%
6.8%CN¥121.70CN¥106.16CN¥73.282
Feb ’24CN¥92.50
CN¥113.93
+23.2%
6.8%CN¥121.70CN¥106.16CN¥68.602
Jan ’24CN¥82.13
CN¥113.93
+38.7%
6.8%CN¥121.70CN¥106.16CN¥96.802
Dec ’23CN¥82.10
CN¥113.93
+38.8%
6.8%CN¥121.70CN¥106.16CN¥94.562
Nov ’23CN¥95.70
CN¥113.93
+19.0%
6.8%CN¥121.70CN¥106.16CN¥87.682

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies